Clinical trial

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

NCT05343117

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2021-12-01

PhaseN/A

Study timeline

Study start (actual)2021-12-01Date precision: day

Registry last updated2022-04-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hormone Receptor Positive Advanced Breast Cancerunresolved

Interventions

Palbociclib based-therapy as initial endocrine therapyDRUG

Palbociclib based-therapy after chemotherapyDRUG

Sponsors & collaborators

Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China8

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05343117 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.